Table 2.

Time to Progress and Progression-Free Survival According to Characteristic Features of the Patients and Type of Salvage Therapy (N=66)

Characteristic features	Time to progress (month; range)	PFS, median (month; 95% CI)	Unadjusted HR (%; 95% CI)	Adjusted HR (%; 95% CI)
Age			0.69 (0.32-0-1.48)	1.17 (0.49-2.78)
≤ 40 years (n=12)	4.1 (0.4-64)	3.30 (0.00-7.47)
> 40 years (n=54)	10.9 (0.2-62.5)	12.30 (8.86-15.74)
Stage			1.81 (1.02-3.23)	1.65 (0.82-3.13)
II (n=37)	9.8 (0.2-64)	12.37 (1.98-22.76)
III-IV (n=29)	6.9 (0.3-62.5)	10.47 (2.94-17.99)
Performance status			1.59 (0.88-2.86)	1.92 (1.02-3.62)
0-1 (n=63)	9.8 (0.2-64)	11.23 (7.31-15.16)
2-4 (n=3)	1.4 (0.4-17.9)	1.37 (7.21-15.25)
Treatment-free interval			0 (0-0.16)	0 (0-0.14)
≤ 6 months (n=25)	2.9 (0.2-5.5)	2.93 (1.68-4.19)
> 6 months (n=41)	16.5 (6.1-64)	18.62 (3.50-34.16)
Type of failures			0.73 (0.72-1.60)	0.19 (0.87-2.07)
Local (n=45)	17.1 (0.3-64.0)	10.5 (6.9-14.1)
Systemic (n=26)	16.5 (0.2-59.5)	15.4 (6.8-23.9)
Local and Systemic (n=14)	10.0 (0.4-40.2)	7.6 (1.6-13.6)
Primary treatment			1.61 (0.90-2.87)	1.47 (0.75-2.87)
CCRT (n=34)	12.3 (0.3-59.5)	12.37 (6.96-17.78)
CCRT+ACT (n=32)	6.8 (0.2-64)	8.03 (2.16-13.91)
Salvage therapy			1.25 (0.92-1.71)	1.02 (0.77-1.35)
Radiation therapy (n=8)	12.1 (2.1-27.6)	12.90 (8.69-17.11)
Surgery (n=2)	46.9 (29.8-64)	29.80 (18.4-72.6)
Chemotherapy (n=29)	8.5 (0.3-62.5)	9.83 (2.41-17.25)
Combined treatment (n=18)	15.1 (2.3-59.5)	23.07 (4.07-42.07)
Supportive care (n=9)	1.4 (0.2-4.5)	2.93 (0-2.82)

Note: Performance status referred to performance status of the patients at the time of event; Time to progress referred to duration from the start of salvage therapy to progression of disease; Treatment-free interval referred to duration from the last date of primary treatment to the date of even